| Document |
Document Title |
|
WO/2024/006881A1 |
Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment WEE1 associated diseases such as cancer.
|
|
WO/2024/006781A1 |
The application relates to bifunctional compounds of the general formula I-3' which act as degraders of the estrogen receptor alpha(ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such a...
|
|
WO/2024/003915A1 |
A crystalline form of indaziflam, processes for the preparation thereof, an agrochemical composition containing the crystalline form of indaziflam and a process for the preparation of the agrochemical composition.
|
|
WO/2024/002853A1 |
A precursor compound and radiotracer for targeting fibroblast activation protein comprise a chelator Ch and ligand TV with Ch = (Formula) with R = | ‒CH3 or |‒CH2COOH; and TV = (Formula).
|
|
WO/2024/000401A1 |
The present invention relates to compounds of formula (I) preferred compounds are e.g. 2-((l-(4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)benzoic acid derivatives of formula (ll-A) an exemplary compound is e.g. 2-((l-(2-(isoindolin-2-yl...
|
|
WO/2024/000763A1 |
Provided are a G9a/GLP covalent inhibitor and a preparation method therefor and a use thereof. The G9a/GLP covalent inhibitor is a compound having a structure as shown in formula (I) and a salt thereof:
|
|
WO/2024/003259A1 |
The present invention covers heterocyclic compounds of general formula (I): Formula (I), wherein (I'), Formula (I') represents a heterocyclic ring, said compound of general formula (I) being selected from the group consisting of: Formula...
|
|
WO/2024/005578A1 |
The present invention relates to novel indenone derivatives, isomers thereof or pharmaceutically acceptable salts thereof, and uses thereof. The indenone derivatives according to the present invention may be advantageously used for (i) t...
|
|
WO/2024/005032A1 |
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
|
|
WO/2024/002379A1 |
Provided are a compound used as a WDR5 inhibitor or a pharmaceutically acceptable salt thereof, and a use of the compound in preparation of a drug. The compound has high affinity to WDR5, and compared with the prior art, has higher inhib...
|
|
WO/2024/005486A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting element comprising same.
|
|
WO/2024/002353A1 |
Provided are a pharmaceutically acceptable salt and a crystal form of a nitrogen-containing bridge heterocyclic derivative, and a method for preparing same. Specifically provided are different salt forms and crystal forms of salts of 4-(...
|
|
WO/2024/002223A1 |
The present invention relates to a heterocyclic derivative as an inhibitor, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by general formula (I), a method for prepari...
|
|
WO/2024/006982A1 |
The present disclosure provides compounds and salts thereof, and compositions, which are useful in the prevention and/or treatment of HIV.
|
|
WO/2024/006897A1 |
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
|
|
WO/2023/250029A1 |
The present disclosure provides certain bifunctional compounds containing substituted pyrimidine derivatives substituted at the 4-position with a cyclic group that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin prote...
|
|
WO/2023/246873A1 |
Disclosed in the present application are a series of amino-substituted heteroaryl derivatives and a use thereof. In particular, disclosed are a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/249873A2 |
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2023/246656A1 |
The present invention belongs to the technical field of medicinal chemistry, and relates to an SOS1 proteolysis targeting chimera and a composition, a preparation and the use thereof. Specifically, the general formula structure of the ch...
|
|
WO/2023/246677A1 |
The present application relates to the technical field of chemical drugs, and particularly, to a compound represented by general formula (I), a racemate thereof, an isomer thereof or a pharmaceutically acceptable salt thereof as a comple...
|
|
WO/2023/250399A1 |
Described herein are compounds of Formula (I), methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 (...
|
|
WO/2023/247563A1 |
A compound of formula (I-A), R1 in each occurrence is selected from H, optionally substituted C1-12 alkyl and optionally substituted C6-20 aryl; R2 in each occurrence is selected from optionally substituted C1-12 alkyl and optionally sub...
|
|
WO/2023/249980A1 |
Provided herein are BTK inhibitors containing piperidine modified at the 3-position. Further disclosed are methods of making and using said BTK inhibitors.
|
|
WO/2023/247670A1 |
The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...
|
|
WO/2023/250335A1 |
The present disclosure relates to compounds of Formula (I): The compounds disclosed herein are useful for modulating PD-1 activity, PD-L1 activity (programmed cell death protein 1), and/or the PD-1/PD-L1 interaction and may be used in th...
|
|
WO/2023/249469A1 |
A novel thalidomide derivative developed in the invention has an excellent binding ability with respect to cereblon, has almost no cytotoxicity, and is unlikely to cause teratogenic side effects, and, thus, has the advantage of being abl...
|
|
WO/2023/248871A1 |
Provided are a compound represented by formula (I), etc. (wherein: Z represents an oxygen atom, etc.; R1, R2, R3 and R4 each independently represent a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group; Y1 and Y2 each indep...
|
|
WO/2023/249516A1 |
The invention relates to the fields of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form of 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione and to a pharmac...
|
|
WO/2023/249471A1 |
The present invention relates to a novel immunoregulatory amide derivative, a preparation method therefor, and use thereof. The novel immunoregulatory amide derivative developed in the present invention has an excellent binding ability w...
|
|
WO/2023/246371A1 |
The present application discloses a small molecule compound having a pyrimidothiophene structure, and a use thereof. By means of inhibiting activity of the cyclin-dependent kinase (CDK) family, the small molecule compound can block the c...
|
|
WO/2023/249470A1 |
The present invention relates to novel pomalidomide derivatives and a preparation method therefor. A compound according to the present invention has increased binding strength to cereblon compared to pomalidomide and also reduces teratog...
|
|
WO/2023/247488A1 |
Compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein R2, R3, R5, R6, R7, and R8 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of ...
|
|
WO/2023/249871A1 |
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2023/247754A1 |
The present invention relates to bifunctional molecules which contain a protein-of-interest binding moiety linked through a linker group to a cellular receptor binding moiety preferably a moiety which binds to the receptor sortilin encod...
|
|
WO/2023/250181A1 |
Provided is a compound having the structure of Formula (1) or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, Ri, R2, R3, R4, R5, R6, R7, m, 11, p, and y are as defined herein, for use in methods fo...
|
|
WO/2023/246839A1 |
The present invention provides a salt of a compound with GLP-1R agonist activity, as represented by formula (I), and/or a crystal form, and preparation and pharmaceutical use, wherein a pharmaceutically acceptable salt is selected from a...
|
|
WO/2023/248174A1 |
The present invention relates to an improved process for the preparation of Voxelotor and its key intermediate (2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methanol, a compound of Formula IV, produced by utilizing a Suzuki cross-coupling...
|
|
WO/2023/246732A1 |
Disclosed are a benzoheterocyclic substituted tetrahydroisoquinoline compound salt form and a preparation method therefor. Specifically, disclosed are an amorphous form and salt form of the compound as shown in formula (I), and a use the...
|
|
WO/2023/242099A1 |
The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders inflammatory diseases and/or genetic disorders. The present invention r...
|
|
WO/2023/244817A1 |
Described herein, in part, are compounds that mediate the degradation of casein kinase 1α (CK1α), and are therefore useful in the treatment of various disorders, such as cancer.
|
|
WO/2023/245137A1 |
Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof. Also provided herein is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a stereoisomer or tautomer thereof, or...
|
|
WO/2023/241103A1 |
The present application relates to the technical field of electronic cigarettes, and in particular, to a composite nicotine salt, a composite nicotine salt formulation and a preparation method therefor and a use thereof. The composite ni...
|
|
WO/2023/241322A1 |
Provided are heterocyclic derivatives as shown in Formula (I), pharmaceutical compositions comprising them, a process for their preparation, and their use as therapeutic agents.
|
|
WO/2023/244918A1 |
This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), or (I-aa-4)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), or (I-a-4)), Formula (I-bb) (e.g., Formula (I-bb-1...
|
|
WO/2023/241507A1 |
Disclosed in the present invention are a crystal form of an alkynylpyridine compound and a preparation method therefor, specifically disclosed are a crystal form of a compound represented by formula (I) and a preparation method therefor.
|
|
WO/2023/243677A1 |
The present invention provides a plant disease control method having an excellent efficacy for controlling plant diseases, the method comprising treating plants or soil used for plant cultivation with a compound represented by formula (I...
|
|
WO/2023/244574A1 |
Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions,...
|
|
WO/2023/244818A1 |
Described herein, in part, are compounds that mediate the degradation of casein kinase 1α (CK1α), and are therefore useful in the treatment of various disorders, such as cancer.
|
|
WO/2023/241608A1 |
The present application relates to compounds of formula (I) and formula (1'), which are useful as inhibitors of CSF-1R in the treatment of various diseases.
|
|
WO/2023/241652A1 |
The present invention provides a pharmaceutical composition, a method for preparing same, and use thereof. The pharmaceutical composition comprises a compound represented by formula I. The pharmaceutical composition of the present invent...
|
